In the latest trading session,, 0.56 million Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares changed hands as the company’s beta touched 1.91. With the company’s most recent per share price at $5.05 changing hands around $0.14 or 2.75% at last look, the market valuation stands at $1.04B. BCRX’s current price is a discount, trading about -79.41% off its 52-week high of $9.06. The share price had its 52-week low at $4.82, which suggests the last value was 4.55% up since then. When we look at Biocryst Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 3.95 million shares, with the 3-month average coming to 3.31 million.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information
Instantly BCRX is in green as seen in intraday trades today. With action -5.88%, the performance over the past five days has been red. The jump to weekly highs of 5.86 added 2.75% to the stock’s daily price. The company’s shares are showing year-to-date downside of -15.78%, with the 5-day performance at -5.88% in the red. However, in the 30-day time frame, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) is -12.87% down. Looking at the short shares, we see there were 29.1 million shares sold at short interest cover period of 9.88 days.
Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts
Data shows that the Biocryst Pharmaceuticals Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -31.55% over the past 6 months, a 38.00% in annual growth rate that is considerably higher than the industry average of 10.50%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Biocryst Pharmaceuticals Inc. will rise 25.00%, while the growth in revenue is estimated to hit 60.00% for the next quarter. Year-over-year growth is forecast to reach 19.40% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of $86.29 million. 9 analysts are of the opinion that Biocryst Pharmaceuticals Inc.’s revenue for the quarter ending Jun 2024 will be $98.6 million. The company’s revenue for the corresponding quarters a year ago was $68.78 million and $82.49 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 25.50%. The estimates for the next quarter sales put growth at 19.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -3.73%. The 2024 estimates are for Biocryst Pharmaceuticals Inc. earnings to increase by 46.44%, but the outlook for the next 5-year period is at 44.80% per year.
BCRX Dividends
Biocryst Pharmaceuticals Inc. is expected to release its next quarterly earnings report between May 01 and May 06.
Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.22% of Biocryst Pharmaceuticals Inc. shares while 88.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.14%. There are 88.05% institutions holding the Biocryst Pharmaceuticals Inc. stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 8.18% of the shares, roughly 15.5 million BCRX shares worth $109.09 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 7.96% or 15.09 million shares worth $106.23 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 8.22 million shares estimated at $58.41 million under it, the former controlled 4.34% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.09% of the shares, roughly 5.86 million shares worth around $41.26 million.
